Strategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomes.


Journal Article (Review)

The burden of chronic hepatitis C virus (HCV) infection is significant and growing. HCV is considered one of the leading causes of liver disease worldwide and the leading cause of liver transplantation globally. While those infected is estimated in the hundreds of millions, this is likely an underestimation because of the indolent nature of this disease when first contracted. Approximately 20% of patients with HCV infection will progress to advanced fibrosis and cirrhosis. Those that do are at risk of decompensated liver disease including GI bleeding, encephalopathy, severe lab abnormalities, and hepatocellular carcinoma. Those individuals with advanced fibrosis and cirrhosis have historically been difficult to treat. The backbone of previous HCV regimens was interferon (IFN). The outcomes for IFN based regimens were poor and resulted in increased adverse events among those with advanced fibrosis and cirrhosis. Now, in the era of new direct acting antiviral (DAA's) medications, there is hope for curing chronic HCV in everyone, including those with advanced fibrosis and cirrhosis. This article provides a review on the most up to date data on the use of DAA's in patients with advanced fibrosis and cirrhosis. We are at a point where HCV could be truly eradicated, but to do so will require ensuring there are effective and safe treatments for those with advanced fibrosis and cirrhosis.

Full Text

Duke Authors

Cited Authors

  • Wilder, JM; Muir, AJ

Published Date

  • November 2015

Published In

Volume / Issue

  • 6 / 6

Start / End Page

  • 314 - 327

PubMed ID

  • 26568808

Pubmed Central ID

  • 26568808

Electronic International Standard Serial Number (EISSN)

  • 2040-6231

International Standard Serial Number (ISSN)

  • 2040-6223

Digital Object Identifier (DOI)

  • 10.1177/2040622315603642


  • eng